Saturday 17 October 2026
Export KRSA’s income statement to Excel — free account
Korsana Biosciences, Inc.
KRSA Healthcare Biotechnology
In the quarter to June 2026, revenue fell 43.2%, EPS fell 272.7% and free cash flow fell 184.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
32.38
1.27
−3.77%
Follow KRSA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 1.95 | 2.60 | |
P/FCF ratio |
— | — | 0.00 | 90.49 | |
P/Operating CF |
— | — | (2.56) | (28.11) | |
P/B ratio |
— | — | 0.44 | 0.78 | |
Price to Tangible BV |
— | — | 0.44 | 0.78 | |
EV/Sales |
— | — | 0.39 | 1.00 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (0.24) | (2.07) | |
EV/FCF |
— | — | (0.43) | 34.79 | |
Quick Ratio |
0.75 | 1.65 | 4.71 | 5.32 | |
Current Ratio |
0.82 | 1.80 | 5.15 | 5.78 | |
Net Debt/EBITDA |
0.79 | 0.88 | 3.87 | 4.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.21 | 0.30 | |
Operating CF/Net income |
0.82 | 0.37 | 1.98 | 0.27 | |
Capex/Depreciation |
0.00 | 0.00 | — | — | |
Research and Development Expense of Revenue |
— | 0.00% | 50.63% | 39.77% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 131.12% | 175.20% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 9.27% | 13.49% | |
Graham Net Nets |
— | — | 0.92 | 0.56 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (91.31%) | (32.60%) | |
Free Cash Flow Yield |
— | — | (45.95%) | 1.11% | |
Revenue per Share |
0.00 | 0.00 | 2.25 | 1.90 | |
Operating CF per Share |
(2.36) | (1.96) | (3.47) | (0.57) | |
Capex per Share |
0.00 | (0.11) | 0.00 | 0.00 | |
Free Cash Flow per Share |
(2.36) | (2.07) | (3.47) | (0.57) | |
Cash per Share |
2.29 | 4.70 | 7.13 | 9.91 | |
Shareholders Equity per Share |
8.37 | 11.30 | 19.98 | 20.69 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
8.37 | 11.30 | 19.98 | 20.69 | |
Free Cash Flow |
(1.43) | (1.24) | (1.58) | (0.26) | |
Working Capital |
(0.33) | 1.38 | 3.74 | 4.19 | |
Capital Expenditures |
0.00 | (0.07) | — | — | |
Net Current Asset Value |
(0.33) | 1.38 | 3.74 | 4.19 | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 0.78 | 0.07 | |
Average Payables |
1.03 | 0.47 | 0.45 | 0.39 | |
Average Assets |
8.15 | 9.18 | 9.78 | 9.66 | |
Average Common Equity |
6.83 | 7.79 | 8.97 | 8.87 |
Columns are period end dates